Sunlife Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 17-07-2024
- Paid Up Capital ₹ 0.57 M
as on 17-07-2024
- Company Age 15 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue 126.98%
(FY 2023)
- Profit 5.08%
(FY 2023)
- Ebitda 601.45%
(FY 2023)
- Net Worth 3.61%
(FY 2023)
- Total Assets 82.47%
(FY 2023)
About Sunlife Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.57 M, as per Ministry of Corporate Affairs (MCA) records.
Priyanka Mishra, Devendra Mishra, and Bachchalal Yadawa serve as directors at the Company.
- CIN/LLPIN
U74990MH2009PLC197290
- Company No.
197290
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
24 Nov 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Kalyan, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Sunlife Pharmaceuticals Limited offer?
Sunlife Pharmaceuticals Limited offers a wide range of products and services, including Common Disease Medicines, Eye Care Medicines, Digestive System Drugs & Medicines, Antacid Drugs, Antibiotic Tablets & Capsules, Azithromycin Tablets, Cefpodoxime Proxetil Capsules, Hand Sanitizer & Disinfectant, Alcohol Based Hand Sanitizer, Antifungal Injection, Tablet & Syrup.
Who are the key members and board of directors at Sunlife Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Priyanka Mishra  | Director | 01-Apr-2016 | Current |
| Devendra Mishra | Director | 01-Apr-2016 | Current |
| Bachchalal Yadawa | Director | 12-Jan-2017 | Current |
Financial Performance of Sunlife Pharmaceuticals.
Sunlife Pharmaceuticals Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 126.98% increase. The company also saw a slight improvement in profitability, with a 5.08% increase in profit. The company's net worth moved up by a moderate rise of 3.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sunlife Pharmaceuticals?
In 2023, Sunlife Pharmaceuticals had a promoter holding of 85.01% and a public holding of 14.99%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sunlife Pharmaceuticals?
Unlock and access historical data on people associated with Sunlife Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sunlife Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sunlife Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
